XBI Trading Analysis - 11/20/2026 04:18 PM — TRU-SENTIMENT

XBI (State Street SPDR S&P Biotech ETF) at $140.55. True Sentiment Bearish, delta 40-60 call 6% / put 94%, call $339,580 vs put $5,258,655. RSI 35.9.

TRU-SENTIMENT · DeltaNeutral

XBI Trading Analysis - 11/20/2026 04:18 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

XBI (State Street SPDR S&P Biotech ETF) at $140.55. True Sentiment Bearish, delta 40-60 call 6% / put 94%, call $339,580 vs put $5,258,655. RSI 35.9.

Symbol
XBI
Price
$140.55
Article bias (separate from True Sentiment)
bearish
Conviction
medium
Published
2026-11-20 16:18:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment: Bearish. Call dollar volume $339,580.00 (6.1%) vs put dollar volume $5,258,655.00 (93.9%). Total $5,598,235.00. Put contracts 8,099 vs call 527. Pure directional conviction heavily favors puts.

Near-term expectation: strong bearish positioning into 2026-12-18. Divergence: technicals also bearish, so no divergence — sentiment confirms weak price action.

Call Volume: $339,580.00 (6.1%) Put Volume: $5,258,655.00 (93.9%) Total: $5,598,235.00

Note: Delta 40-60 filter shows 82 of 2,368 options analyzed — concentrated directional put buying.

Key Statistics: XBI

$140.55 -2.71%
52-Week Range
$113.57 - $169.89
Market Cap
$9.84B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
1.01
Next Earnings
N/A
Avg Volume
$7.79M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

Market cap$9.84B
Shares outstanding70.0M

Dividend

Dividend yield0.38%
Annual dividend$0.54
Ex-dividend date2026-06-22

Risk & range

Beta1.01
52-week low$113.57
52-week high$169.89
Historical volatility39.2%

Ownership & trading

Institutional ownership7.7%
Average daily volume8.7M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following recent context items are based on general knowledge and are separated from the data-driven analysis below:

  • Biotech sector ETFs like XBI have faced pressure amid ongoing FDA regulatory uncertainty and slower IPO activity in late 2026.
  • Recent broad market rotation out of small-cap and speculative biotech names has weighed on XBI demand.
  • No specific XBI earnings catalyst exists as it is an ETF, but underlying clinical trial results from major holdings have shown mixed outcomes.
  • Macro rate-cut expectations have faded, reducing appetite for high-beta biotechnology exposures.
  • Headlines suggest defensive positioning, which aligns with the heavily bearish options flow and weak technicals in the embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for XBI:

  • Revenue growth (YoY and recent trends): Not available (totalRevenue and revenueGrowth are null).
  • Profit margins (gross, operating, net): Not available (profitMargins is null).
  • Earnings per share (EPS): Not available (trailingEps and forwardEps are null).
  • P/E ratio and valuation: trailingPE and forwardPE are null; pegRatio is null. No valuation multiples can be computed from data.
  • Key concerns: institutionalPercent is only 7.71%, indicating low institutional ownership; priceToBook, debtToEquity, returnOnEquity, freeCashflow all null.
  • Market cap is $9,838,500,000.00 with 70,000,000.00 shares outstanding; dividend yield 0.38% (rate $0.54).
  • 52-week range: low $113.57, high $169.89; beta 1.01; historical volatility 39.24%.
  • Analyst consensus and target: recommendationKey and targetMeanPrice are null — no analyst context in data.
  • Fundamentals show limited fundamental透明度 (many nulls) and low institutional hold; this diverges from technical weakness but offers no bullish offset.

Current Market Position

Current price per indicators is $144.47 (as of 2026-11-19 close). Minute bars show 2026-11-20 15:50:00 close at $140.55, down from 2026-11-19 09:30 open of $145.38. Recent daily history: 2026-11-16 close $145.66, 2026-11-19 close $144.47, with 30-day low $143.24 (2026-11-17) and high $160.29 (2026-10-29).

Intraday momentum: First 5 minute bars on 2026-11-19 opened $145.38 and drifted to $145.31 by 09:50; last 5 minute bars on 2026-11-20 show slide from $140.74 to $140.55 on rising volume (446,012 at 15:50). Weak intraday trend.

Support
$143.24
Resistance
$152.18
Bollinger Lower
$143.33
SMA 20
$152.18

Technical Analysis

Technical Indicators

RSI (14)
35.86
MACD
-2.07
Signal
-1.65
Histogram
-0.41
SMA 5
$146.22
SMA 20
$152.18
SMA 50
$153.08
ATR 14
$5.17

SMA alignment: SMA 5 ($146.22) < SMA 20 ($152.18) < SMA 50 ($153.08) — bearish stack, no bullish crossovers. RSI 35.86 shows bearish momentum near oversold but not extreme. MACD negative with histogram -0.41 confirms downside momentum. Bollinger Bands: middle $152.18, upper $161.04, lower $143.33; price below lower band suggests extended. 30-day range: high $160.29, low $143.24; current $144.47 sits near bottom 8% of range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment: Bearish. Call dollar volume $339,580.00 (6.1%) vs put dollar volume $5,258,655.00 (93.9%). Total $5,598,235.00. Put contracts 8,099 vs call 527. Pure directional conviction heavily favors puts.

Near-term expectation: strong bearish positioning into 2026-12-18. Divergence: technicals also bearish, so no divergence — sentiment confirms weak price action.

Call Volume: $339,580.00 (6.1%) Put Volume: $5,258,655.00 (93.9%) Total: $5,598,235.00

Note: Delta 40-60 filter shows 82 of 2,368 options analyzed — concentrated directional put buying.

Key Price Levels (Observational Only)

30d Low
$143.24
Bollinger Lower
$143.33
SMA 5
$146.22
SMA 20/50
$152.18-$153.08
30d High
$160.29

Interactive charts load with JavaScript. This text is the crawlable summary.